SBC Medical Group Enters U.S. Market Through Strategic Investment in OrangeTwist Medspa Chain

SBC Medical Group Holdings Inc. (NASDAQ: SBC), the Japanese owner and operator of a chain of aesthetic medical clinics, has officially entered the U.S. market through the completion of a strategic investment in OrangeTwist, a U.S.-based medspa chain. This investment represents the beginning of SBC's full-scale strategic expansion in the U.S., leveraging its existing network of 258 affiliated clinics worldwide and more than six million annual patient visits. The partnership will enable joint operations between the companies, combining their strengths in the U.S. and Asian markets.

OrangeTwist specializes in non-invasive aesthetic treatments, operating 24 locations across six U.S. states and offering injectable, energy-based, and regenerative treatments. SBC highlighted OrangeTwist's advanced management system, which integrates procurement, clinical workflows, and real-time KPI tracking, as providing operational consistency with SBC's approach and supporting scalable growth. Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings, stated that OrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine. The companies plan to collaborate on selling each other's services and products in the U.S. and Japan, as well as developing new beauty products and services together.

This deal represents the first step in SBC's multiyear roadmap to establish a leading position in the medical aesthetics and wellness market through international expansion, particularly in the U.S. and Southeast Asia. The U.S. market is particularly important for SBC, with the medical aesthetics industry forecast to grow from $34 billion today to $48 billion by 2030, according to SBC's reports. Demand drivers include injectables, fillers, laser treatments, and body contouring procedures that offer minimal risk and downtime, along with the aging U.S. population seeking aesthetic treatments.

During 2026, SBC plans to make additional strategic investments and partnerships similar to the OrangeTwist arrangement to expand further in the U.S. and Southeast Asia. The company has already established a presence in Southeast Asia through an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics in Thailand. As part of that partnership, SBC will provide management support for a new clinic focused on dermatological treatments that BLEZ is preparing to open in Bangkok. These initial deals represent Phase 1 of SBC's expansion strategy.

Phase 2, scheduled for 2027 and 2028, will focus on select acquisitions and joint ventures to accelerate growth and enhance competitive positioning. Phase 3, beginning in 2029 and beyond, is when SBC expects to achieve leadership positions in the U.S., Southeast Asia, and other key markets. Robert Settembro, CEO of OrangeTwist, expressed enthusiasm about deepening the strategic partnership with SBC Medical Group Holdings while expanding presence in high-growth markets, emphasizing the opportunity to bring exceptional aesthetic experiences to more communities while leveraging SBC's global expertise.